Yellow Fever

1. Overview

Yellow fever (YF) is an acute viral haemorrhagic fever caused by yellow fever virus (YFV), a single-stranded RNA flavivirus transmitted by Aedes and Haemagogus mosquitoes in tropical regions of sub-Saharan Africa and South America. The disease derives its name from the jaundice that affects some patients due to hepatocellular necrosis. Despite the availability of a highly effective live-attenuated vaccine (17D strain) since 1937, yellow fever remains a significant public health threat, with an estimated 200,000 cases and 30,000 deaths annually. [1,2]

The clinical spectrum ranges from asymptomatic or mild febrile illness in approximately 85% of cases to severe disease characterised by hepatorenal failure, haemorrhage, and shock in 15% of infected individuals. The classic biphasic course—an initial viremic phase followed by a brief remission and subsequent "toxic phase" of multi-organ failure—is pathognomonic. Case fatality rates in severe disease exceed 50%, with no specific antiviral therapy available, making prevention through vaccination the cornerstone of disease control. [3,4]

Yellow fever holds historical significance as one of the first diseases proven to be mosquito-borne (Walter Reed, 1900) and the first for which a successful live-attenuated vaccine was developed (Max Theiler, 1937—Nobel Prize 1951). The disease poses ongoing risks to unvaccinated travellers and threatens urban outbreaks in receptive areas with competent Aedes aegypti vectors, including potential spread to Asia where the virus has never established endemicity despite suitable environmental conditions. [5,6]

---

2. Epidemiology

Geographic Distribution

Yellow fever exhibits a distinct geographic distribution limited to two endemic zones, with notable absence from Asia despite the presence of competent vectors:

The African endemic zone extends from 15°N to 10°S latitude, encompassing savanna and rainforest regions. In South America, transmission occurs primarily in the Amazon and Orinoco river basins, with sporadic sylvatic cases. [1,7]

Transmission Cycles

Three distinct epidemiological cycles maintain YFV transmission:

1. Sylvatic (Jungle) Cycle: Mosquitoes (Haemagogus spp. in Americas, Aedes africanus in Africa) transmit virus among non-human primates. Humans are incidental hosts when entering forest environments. This cycle maintains viral circulation indefinitely as a zoonosis. [8]

2. Intermediate (Savanna) Cycle: Occurs only in Africa. Semi-domestic mosquitoes (Aedes spp.) infect both monkeys and humans in rural villages at forest margins. Responsible for small-scale epidemics in Africa. [7]

3. Urban Cycle: Aedes aegypti transmits virus directly between humans in densely populated areas. This cycle has epidemic potential and historically caused devastating outbreaks in the Americas and Africa. Re-urbanisation of YF remains a major public health concern. [9]

Demographics and Risk Factors

• Age: All ages susceptible; severity increases with age > 60 years
• Sex: Male predominance (2:1) reflects occupational forest exposure
• Occupational Risk: Loggers, agricultural workers, military personnel, travellers
• Vaccination Status: Unvaccinated individuals at highest risk; vaccine provides > 95% protection [10]
• Genetic Susceptibility: HLA haplotypes may influence disease severity (under investigation)

Recent Epidemiological Trends

Between 2016-2018, Brazil experienced the largest YF outbreak in decades with > 2,000 confirmed cases, demonstrating viral expansion into previously non-endemic areas and raising concerns about potential urban transmission. Declining vaccination coverage in some endemic countries, increased deforestation bringing humans into contact with sylvatic cycles, and climate change altering vector distribution all contribute to resurgent risk. [11,12]

---

3. Aetiology & Pathophysiology

Virology

Yellow fever virus (YFV) is a member of the Flaviviridae family, genus Flavivirus, closely related to dengue, Zika, West Nile, and Japanese encephalitis viruses. Key virological features:

• Genome: Positive-sense single-stranded RNA (~11 kb)
• Structure: Enveloped virus (40-60 nm diameter)
• Polyprotein Products: Three structural proteins (C, prM, E) and seven non-structural proteins (NS1-NS5)
• Genotypes: Seven genotypes identified—5 African, 2 South American [13]

Pathophysiology

The pathogenesis of yellow fever involves multiple organ systems with complex virus-host interactions:

Initial Infection and Viral Dissemination

Following inoculation by an infected mosquito, YFV initially replicates in regional lymph nodes, particularly targeting dendritic cells and macrophages. After 3-6 days incubation, primary viremia disseminates virus to liver, spleen, kidney, bone marrow, and lymphoid tissues. Peak viremia coincides with onset of symptoms and may reach 10^6-10^8 viral particles per mL. [14]

Hepatic Pathology

The liver bears the brunt of YFV pathology. Virus exhibits specific tropism for mid-zonal hepatocytes (zone 2 of hepatic acinus), causing:

• Direct Viral Cytopathology: YFV replication induces hepatocyte apoptosis via activation of caspase pathways
• Councilman Bodies: Eosinophilic apoptotic hepatocytes are pathognomonic histological finding
• Hepatic Dysfunction: Jaundice results from bilirubin accumulation; coagulopathy from loss of synthetic function (clotting factors II, VII, IX, X) [3,15]

Remarkably, Kupffer cells (liver macrophages) remain relatively spared, distinguishing YF from other viral hepatitides.

Endothelial Injury and Vascular Leak

The NS1 protein secreted by infected cells causes tissue-specific endothelial dysfunction. Studies demonstrate that YFV NS1 selectively binds to and alters permeability of liver endothelial cells through disruption of the endothelial glycocalyx, contributing to hepatic vascular leak, ascites, and third-spacing. This mechanism mirrors pathology in other flavivirus infections but exhibits organ-specific tropism. YFV NS1 serum levels correlate significantly with syndecan-1 (a marker of endothelial glycocalyx degradation and vascular leak), disease severity, and mortality in severe yellow fever patients. [16,46,47]

Renal Pathology

Acute tubular necrosis (ATN) occurs through dual mechanisms:

• Direct Viral Injury: YFV replication in renal tubular epithelium
• Ischaemic Injury: Secondary to hypotension and hepatorenal syndrome [17]

Proteinuria and oliguria are prominent features. Hepatorenal syndrome represents functional renal failure in the setting of severe liver dysfunction.

Haemorrhagic Manifestations

Bleeding results from multifactorial coagulopathy:

• Thrombocytopenia: Direct viral infection of megakaryocytes and platelet consumption
• Clotting Factor Deficiency: Impaired hepatic synthesis of vitamin K-dependent factors
• DIC: Consumptive coagulopathy in severe cases with elevated D-dimer levels indicating fibrinolysis
• Endothelial Damage: Vascular fragility from direct viral and inflammatory injury [18,48]

Recent studies demonstrate that consumptive coagulopathy with D-dimer elevation occurs independently of massive hepatocellular tropism, suggesting infection of non-hepatocyte cell types contributes significantly to coagulation abnormalities in severe yellow fever. [48]

Immunopathology

The host immune response contributes to both viral clearance and pathology:

• Innate Immunity: Type I interferon responses critical for viral control; deficiencies predict severe disease
• Cytokine Storm: Elevated TNF-α, IL-6, IL-10 in severe cases correlate with mortality
• Adaptive Immunity: Neutralising antibodies appear by day 5-7; cellular immunity provides long-lasting protection

The "period of intoxication" (toxic phase) may represent immune-mediated pathology as viral loads decline but clinical condition deteriorates. [19,20]

Exam Detail: Molecular Determinants of Virulence:

Specific viral genetic markers distinguish wild-type from vaccine strains. The 17D vaccine contains 32 nucleotide changes from parent Asibi strain, with critical attenuation mutations in NS2B (I37L and I109L) cooperatively mediating reduced virulence in animal models. These mutations reduce viral replication fitness and neurotropism while maintaining immunogenicity. Understanding these determinants informs vaccine development and risk assessment for vaccine-associated disease. [21]

Genetic Susceptibility:

Polymorphisms in genes encoding pattern recognition receptors (TLR3, RIG-I) and interferon signalling pathways may predispose to severe disease or vaccine-associated adverse events. Ongoing genomic studies aim to identify biomarkers predicting individual risk. [22]

---

4. Clinical Presentation

Incubation Period

3 to 6 days following mosquito bite (range: 3-14 days). Patients are typically asymptomatic during this period but viremia develops 24-48 hours before symptom onset.

Clinical Spectrum

Yellow fever manifestations range from subclinical infection to fulminant disease:

Phase 1: Acute (Infection/Viremic Phase)

Duration: 3-4 days

Cardinal Features:

• Abrupt Onset High Fever: 39-40°C
• Severe Headache: Frontal and retro-orbital
• Myalgia and Back Pain: "Coup de barre" (struck with a bar)—characteristic severe lumbar pain
• Nausea and Vomiting
• Facial Flushing and Conjunctival Injection: "Faget's sign complex"

Faget's Sign: Relative bradycardia despite high fever (pulse-temperature dissociation). Though not pathognomonic (also seen in typhoid, legionellosis), its presence in febrile returned traveller from endemic area is highly suggestive. Occurs in approximately 25% of cases. [23]

Physical examination reveals:

• Toxic appearance
• Facial and conjunctival suffusion
• Epigastric tenderness
• Hepatomegaly (early)

Laboratory Findings:

• Leucopenia (WBC 2-4 x 10^9/L)
• Thrombocytopenia (mild, less than 150 x 10^9/L)
• Elevated transaminases (AST/ALT 200-500 U/L, AST > ALT typically)

Remission Phase

Duration: 24-48 hours

Following 3-4 days of acute symptoms, approximately 85% of patients experience complete symptom resolution and full recovery. The remaining 15% enter a brief remission (hours to 2 days) during which patients may feel relatively well, creating false reassurance. This heralds the toxic phase. [24]

Phase 2: Toxic (Period of Intoxication)

Duration: Variable (3-8 days); associated with high mortality

This severe phase develops in 15% of symptomatic patients and is characterised by multi-organ failure:

Hepatic Manifestations:

• Progressive Jaundice: Deepening icterus (bilirubin often > 200 μmol/L)
• Hepatomegaly followed by liver shrinkage (hepatic necrosis)
• Coagulopathy: Prolonged PT/aPTT, reduced fibrinogen
• Hepatic Encephalopathy: Confusion, delirium, coma (late)

Renal Manifestations:

• Oliguria progressing to anuria
• Proteinuria (albuminuria—historically termed "albuminuric nephritis")
• Elevated Creatinine: Acute kidney injury / hepatorenal syndrome
• Metabolic Acidosis

Haemorrhagic Manifestations:

• Mucosal Bleeding: Gingival haemorrhage, epistaxis
• Gastrointestinal Haemorrhage: Haematemesis ("black vomit" / vomito negro)—pathognomonic sign with poor prognosis
• Petechiae and Ecchymoses
• Visceral Haemorrhage: Including intracerebral bleeding (rare)

Cardiovascular Manifestations:

• Hypotension and Shock: Often refractory
• Myocarditis: ECG changes, arrhythmias, cardiac biomarker elevation
• Bradycardia: Persistent relative bradycardia

Neurological Manifestations:

• Delirium and Agitation
• Seizures (particularly in children)
• Coma: Pre-terminal sign

Laboratory Findings in Toxic Phase:

• AST/ALT: 1,000-10,000 U/L (AST typically > ALT, ratio > 1.5)
• Bilirubin: > 200 μmol/L (conjugated and unconjugated)
• PT/aPTT: Markedly prolonged
• Fibrinogen: Low (less than 1.5 g/L in DIC)
• Platelets: Severe thrombocytopenia (less than 50 x 10^9/L)
• Creatinine: > 300 μmol/L
• Lactate: Elevated in shock

Prognosis of Toxic Phase

Mortality in toxic phase: 50-80% depending on access to intensive care. Death typically occurs 7-10 days after symptom onset from:

• Multi-organ failure
• Refractory shock
• Overwhelming haemorrhage
• Secondary bacterial infection (pneumonia, sepsis)

Survivors who recover from toxic phase typically do so completely without chronic sequelae or viral persistence. Immunity is lifelong. [25]

---

5. Differential Diagnosis

Yellow fever must be distinguished from other causes of fever, jaundice, and haemorrhage in returned travellers or endemic area residents:

Priority Differentials

Clinical Clues Favouring Yellow Fever

✅ Supports YF:

• Travel to endemic area (Africa/South America) within 2 weeks
• Lack of yellow fever vaccination
• Biphasic fever pattern with remission
• Faget's sign (pulse-temperature dissociation)
• AST > ALT (atypical for viral hepatitis)
• "Black vomit" (vomito negro)
• Leucopenia in acute phase

❌ Against YF:

• Travel to Asia only (YF never endemic)
• Documented yellow fever vaccination > 10 days prior
• Gradual symptom onset over 1 week
• ALT >> AST (typical viral hepatitis pattern)
• Absence of haemorrhagic manifestations in icteric patient

Exam Detail: Diagnostic Challenges in Co-endemic Areas:

In regions where multiple arboviruses co-circulate (e.g., Amazon basin with YF, dengue, Zika, Orocunga), serological cross-reactivity complicates diagnosis. Plaque reduction neutralisation tests (PRNT) provide the most specific serological differentiation but are time-consuming. RT-PCR during acute viremia (less than 7 days) offers optimal specificity. Clinical acumen and epidemiological context remain paramount. [26]

---

6. Investigations

Specific Diagnostic Tests

Viral Detection (Acute Phase: Days 1-7)

1. RT-PCR (Reverse Transcriptase Polymerase Chain Reaction)

   • Specimen: Serum, plasma
   • Timing: Most sensitive in first 3-4 days of illness (during viremia)
   • Sensitivity: > 95% when performed during viremic phase
   • Advantages: Highly specific, rapid (24-48 hours), quantitative
   • Limitations: Requires specialised laboratory, false negatives after day 5-7

2. Viral Isolation

   • Specimen: Serum
   • Method: Inoculation of Vero or mosquito cell culture
   • Timing: First 4 days
   • Advantages: Gold standard for definitive diagnosis, allows viral characterisation
   • Limitations: Requires BSL-3 containment, slow (7-14 days), rarely used clinically

Serological Tests (Convalescent Phase: Day 5 onwards)

3. IgM Capture ELISA

   • Timing: IgM detectable from day 5-7, peaks at 2 weeks, persists 2-3 months
   • Sensitivity: 85-95%
   • Specificity: 60-80% (cross-reactivity with other flaviviruses—dengue, Zika, WNV)
   • Interpretation: Single IgM positive in compatible clinical context = presumptive diagnosis

4. Plaque Reduction Neutralisation Test (PRNT)

   • Gold Standard Serology: Most specific antibody test
   • Method: Measures virus-specific neutralising antibodies
   • Timing: Requires convalescent serum (> 14 days)
   • Specificity: > 95% (distinguishes cross-reactive antibodies)
   • Limitations: Technically demanding, requires specialised laboratory, slow (5-7 days)

5. IgG Serology

   • Timing: Appears day 7-10, persists for life
   • Use: Diagnosis requires 4-fold rise in paired sera (acute and convalescent)
   • Interpretation: Single IgG positive indicates past infection or vaccination (not acute disease)

General Laboratory Investigations

Haematology

• Full Blood Count:
  • "Leucopenia: 2-4 x 10^9/L (acute phase)—lymphopenia initially, may develop leucocytosis with secondary bacterial infection"
  • "Thrombocytopenia: Progressively worsening (acute phase 100-150 x 10^9/L; toxic phase less than 50 x 10^9/L)"
  • "Haemoconcentration: Elevated haematocrit from vascular leak"

Biochemistry

• Liver Function Tests:

  • "AST/ALT Elevation: 200-500 U/L (acute phase) → 1,000-10,000 U/L (toxic phase)"
  • "AST > ALT: Characteristic pattern (ratio > 1.5, often > 2)—distinguishes from typical viral hepatitis"
  • "Bilirubin: Conjugated and unconjugated elevation (total often > 200 μmol/L in toxic phase)"
  • "Albumin: Low (hepatic synthetic dysfunction)"
  • "Alkaline Phosphatase: Modest elevation (unlike obstructive jaundice)"

• Renal Function:

  • "Creatinine: Progressive rise (> 300 μmol/L in toxic phase)"
  • "Urea: Elevated (pre-renal + intrinsic renal failure)"
  • "Electrolyte Disturbances: Hyperkalaemia, hyponatraemia, metabolic acidosis"

Coagulation Studies

• Prothrombin Time (PT): Prolonged (INR > 2 in toxic phase)
• Activated Partial Thromboplastin Time (aPTT): Prolonged
• Fibrinogen: Low (less than 1.5 g/L) in DIC
• D-dimer: Markedly elevated in DIC
• Clotting Factors: II, VII, IX, X deficiency (hepatic synthetic failure)

Urinalysis

• Proteinuria: Prominent albuminuria (2+ to 4+)—historically used as prognostic marker
• Haematuria: May be present
• Urinary Casts: Granular and epithelial casts (ATN)

Cardiac Biomarkers

• Troponin: Elevated in myocarditis (up to 30% of severe cases)
• ECG: ST-T wave changes, arrhythmias, AV block, bradycardia

Imaging

• Ultrasound Abdomen: Hepatomegaly (early), ascites (late), assess for alternative diagnoses
• Chest X-ray: Pulmonary oedema, pleural effusions (fluid overload vs ARDS)
• CT Imaging: Generally not required; may show hepatomegaly, free fluid

Diagnostic Criteria (Brighton Collaboration Case Definition)

Confirmed Case:

• Compatible clinical illness AND
• Laboratory confirmation:
  • RT-PCR positive, OR
  • Virus isolation, OR
  • IgM seroconversion or 4-fold rise in IgG titre, OR
  • PRNT positive

Probable Case:

• Compatible clinical illness in endemic area AND
• Single IgM ELISA positive (without confirmatory PRNT)

Suspected Case:

• Compatible clinical syndrome with epidemiological linkage (endemic area exposure, unvaccinated) but lacking laboratory confirmation

Exam Detail: Post-Mortem Diagnosis:

Historically, yellow fever was confirmed at autopsy by characteristic liver histopathology:

• Councilman Bodies: Eosinophilic apoptotic hepatocytes
• Mid-zonal Necrosis: Zone 2 hepatocytes preferentially affected
• Microvesicular Steatosis: Fat accumulation in hepatocytes
• Minimal Inflammatory Infiltrate: Despite extensive necrosis

Modern diagnosis relies on immunohistochemistry for viral antigens or PCR on liver tissue. Post-mortem liver biopsy is contraindicated in living patients due to severe coagulopathy. [27]

---

7. Management

Fundamental Principle

There is no specific antiviral therapy for yellow fever. Management is entirely supportive, focusing on haemodynamic stabilisation, correction of coagulopathy, renal support, and prevention of secondary bacterial infection. Intensive care unit admission is mandatory for severe cases.

Acute Management (All Suspected Cases)

Immediate Actions

1. Isolation and Vector Control:

   • Mosquito-proof Environment: Patient must be isolated under bed nets or in screened room during viremic phase (first 5 days) to prevent local mosquito acquisition and potential urban outbreak
   • Blood and Body Fluid Precautions: Standard precautions (not airborne)

2. Initial Stabilisation:

   • ABC Assessment: Airway, breathing, circulation
   • Intravenous Access: Large-bore cannula, fluid resuscitation if hypotensive
   • Baseline Investigations: FBC, U&Es, LFTs, coagulation, VBG, Group & Save

3. Notification:

   • Yellow fever is a notifiable disease internationally (WHO International Health Regulations)
   • Immediate notification to public health authorities required

Supportive Care: Mild to Moderate Disease

Setting: High-dependency unit or monitored ward

• Fluid Management:

  • Maintain euvolaemia with intravenous crystalloid (Hartmann's or 0.9% saline)
  • Target urine output > 0.5 mL/kg/hr
  • "Avoid Fluid Overload: Risk of pulmonary oedema and ARDS"

• Symptomatic Treatment:

  • "Antipyretics: Paracetamol for fever (avoid NSAIDs and aspirin—bleeding risk)"
  • "Antiemetics: Ondansetron, metoclopramide as needed"
  • "Analgesia: Paracetamol; avoid NSAIDs"

• Monitoring:

  • 4-hourly vital signs, fluid balance, daily bloods (FBC, U&E, LFTs, coagulation)
  • Watch for progression to toxic phase (worsening jaundice, bleeding, oliguria)

Management of Severe Disease (Toxic Phase)

Setting: Intensive Care Unit

Haemodynamic Support

• Fluid Resuscitation:

  • "Crystalloid: 20-30 mL/kg boluses titrated to mean arterial pressure > 65 mmHg"
  • "Cautious Approach: Balance between hypoperfusion and fluid overload; consider invasive monitoring (arterial line, CVP)"

• Vasopressors (if refractory hypotension despite fluids):

  • "Noradrenaline: First-line agent (0.05-0.5 μg/kg/min)"
  • Target MAP > 65 mmHg
  • Early initiation reduces cumulative fluid administration and pulmonary oedema risk

Correction of Coagulopathy

• Fresh Frozen Plasma (FFP):

  • "Indications: Active bleeding with prolonged PT/aPTT"
  • "Dose: 10-15 mL/kg; repeat based on ongoing bleeding and coagulation studies"
  • "Aim: INR less than 2 if active haemorrhage"

• Platelet Transfusion:

  • "Indications: Active bleeding with platelet count less than 50 x 10^9/L; prophylactic if less than 10 x 10^9/L"
  • "Dose: 1 adult therapeutic dose (ATD)"

• Vitamin K:

  • 10 mg IV once daily (hepatic synthetic dysfunction impairs vitamin K-dependent factor production)
  • Limited efficacy in severe liver failure but minimal risk

• Cryoprecipitate (if fibrinogen less than 1 g/L with ongoing bleeding)

• Avoid: Recombinant Factor VIIa (no evidence; risk of thrombosis)

Gastrointestinal Bleeding Prevention/Management

• Proton Pump Inhibitor: Pantoprazole 40 mg IV BD or esomeprazole 40 mg IV BD
• Nasogastric Tube: Avoid unless essential (risk of epistaxis/haemorrhage)
• Active GI Bleeding: Correct coagulopathy, consider endoscopy if persistent (high risk; rarely feasible)

Renal Support

• Acute Kidney Injury Management:

  • Optimise haemodynamics (fluids, vasopressors)
  • Avoid nephrotoxins (NSAIDs, aminoglycosides, contrast)
  • Adjust drug doses for renal impairment

• Renal Replacement Therapy (RRT):

  • "Indications: Refractory hyperkalaemia (K+ > 6.5 mmol/L), severe metabolic acidosis (pH less than 7.2), fluid overload with pulmonary oedema, uraemia (urea > 30 mmol/L)"
  • "Modality: Continuous venovenous haemofiltration (CVVH) preferred in haemodynamically unstable patients; intermittent haemodialysis if stable"
  • "Anticoagulation Challenge: Use regional citrate anticoagulation if possible (avoid heparin due to bleeding risk)"

Respiratory Support

• Oxygen Therapy: Maintain SpO₂ > 94%
• Mechanical Ventilation:
  • "Indications: Respiratory failure (PaO₂/FiO₂ less than 200), impaired consciousness (GCS less than 8), refractory shock"
  • Protective lung ventilation (tidal volume 6 mL/kg, PEEP titration) if ARDS

Other Supportive Measures

• Nutritional Support: Enteral feeding if tolerated; parenteral if ileus or shock
• Stress Ulcer Prophylaxis: PPI as above
• Glycaemic Control: Target glucose 6-10 mmol/L (avoid tight control—hypoglycaemia risk in liver failure)
• Monitoring: Invasive BP, CVP, urine output (catheterise), daily bloods including lactate

Investigational Therapies

Sofosbuvir

• Mechanism: NS5B polymerase inhibitor (licensed for Hepatitis C) demonstrates in vitro and in vivo activity against YFV [28]
• Evidence: Case reports of successful use as post-exposure prophylaxis in high-risk vaccine recipients (thymectomy patients accidentally vaccinated) [29]
• Dose: 400 mg PO daily for 14 days
• Status: Off-label use; ongoing clinical trials for treatment and post-exposure prophylaxis
• Consideration: May be offered in specialist centres for confirmed cases or high-risk post-vaccination exposures (discuss with infectious diseases/virology expert)

Other Agents Under Investigation

• Ribavirin: Broad-spectrum antiviral; limited in vitro activity; no clinical evidence
• Favipiravir: RNA polymerase inhibitor; in vitro activity; no clinical data for YF

Current Consensus: No proven antiviral therapy; supportive care remains standard of care. [30]

Management of Complications

Infection Control and Public Health Measures

• Isolation: Until afebrile or day 5 (end of viremic period)
• Contact Tracing: Identify other at-risk travellers
• Vector Control: Intensified mosquito surveillance and control measures in area of importation (if receptive)
• Vaccination Campaign: Ring vaccination of contacts and at-risk populations if outbreak suspected

---

8. Prevention and Vaccination

Yellow Fever 17D Vaccine

The yellow fever vaccine is considered one of the most effective vaccines ever developed. It is a live-attenuated vaccine derived from the 17D strain developed by Max Theiler in 1937.

Vaccine Strains

Two sub-strains in current use:

• 17DD: Produced by Bio-Manguinhos (Brazil)
• 17D-204: Used in YF-VAX (USA) and Stamaril (Europe/elsewhere)

Both provide equivalent protection. [31]

Efficacy and Immunogenicity

• Seroconversion Rate: > 95% by day 10 post-vaccination in immunocompetent individuals
• Neutralising Antibody Levels: Protective titres (≥1:10 by PRNT) achieved in 99% by day 30
• Duration of Protection: Lifelong immunity after single dose (WHO removed 10-year booster recommendation in 2016 based on persistent antibody titres and absence of documented vaccine failures). Studies demonstrate seropositivity rates of 83-93% maintained 10 years post-vaccination across various dose levels. [10,32,49,50]
• Efficacy: Near 100% protection against clinical disease; vaccine breakthrough infections are extremely rare (estimated \u003c1% over 8 decades of use) [49]

Vaccination Schedule

• Standard: Single 0.5 mL dose subcutaneously or intramuscularly
• Timing Before Travel: Minimum 10 days before entry to endemic area (allows immunity to develop and meets International Certificate requirements)
• Booster: No longer recommended for routine travellers; consider booster for highest-risk individuals (laboratory workers, prolonged endemic area residence) or special populations (pregnant women, immunosuppressed receiving initial dose)

International Certificate of Vaccination or Prophylaxis (ICVP)

• "Yellow Card": Official WHO document certifying vaccination
• Validity: Lifetime (since 2016 amendment)
• Requirements: Many countries require ICVP for entry if arriving from endemic countries to prevent viral importation and urban outbreaks
• Administration: Only designated Yellow Fever Vaccination Centres can issue valid certificates

Indications for Vaccination

1. Travellers:

   • Travel to endemic areas (34 African countries, 13 South American countries)
   • Countries requiring proof of vaccination for entry

2. Residents:

   • Routine childhood vaccination in endemic countries (WHO recommendation: include in EPI at 9 months)
   • Catch-up campaigns for unvaccinated populations

3. Occupational:

   • Laboratory personnel working with YFV (BSL-3 facilities)

4. Outbreak Response:

   • Ring vaccination around cases

Contraindications

Absolute Contraindications

1. Severe Hypersensitivity to Vaccine Components:

   • Egg protein (vaccine produced in chick embryos)
   • Gelatin
   • Previous severe reaction to yellow fever vaccine

2. Thymus Disorders:

   • Thymoma (current or historical)
   • Thymectomy (any reason, any age)
   • Myasthenia Gravis (associated with thymus dysfunction)
   • Risk: 5-10 fold increased risk of YEL-AVD [33,34]

3. Severe Immunodeficiency:

   • HIV: CD4 count less than 200 cells/μL or less than 15% in children (or AIDS-defining illness regardless of CD4)
   • Primary Immunodeficiencies: Severe combined immunodeficiency, DiGeorge syndrome, etc.
   • Immunosuppressive Therapy:
     • High-dose corticosteroids (> 20 mg prednisolone equivalent daily for > 14 days)
     • Chemotherapy
     • Biological agents (anti-TNF, rituximab, etc.)
   • Malignancy: Leukaemia, lymphoma

4. Infants less than 6 Months:

   • Absolute contraindication due to risk of vaccine-associated neurotropic disease (YEL-AND) [35]

Relative Contraindications (Risk-Benefit Assessment Required)

1. Age > 60 Years:

   • 3-4 fold increased risk of YEL-AVD and YEL-AND
   • Risk increases with age (highest > 75 years)
   • Approach: Careful risk-benefit analysis; if travel is truly necessary and risk cannot be mitigated, vaccinate with informed consent; if risk is low or travel optional, avoid [36]

2. Infants 6-9 Months:

   • Increased YEL-AND risk but lower than less than 6 months
   • Vaccinate only if travel to high-risk endemic area unavoidable

3. Pregnancy:

   • Theoretical teratogenicity risk (live virus)
   • Lower antibody response (seroconversion ~40%)
   • Approach: Avoid unless travel to high-risk area essential; if vaccinated, consider booster post-pregnancy [37]

4. Breastfeeding:

   • Rare cases of YEL-AND in breastfed infants (vaccine virus transmitted in breastmilk)
   • Approach: Avoid vaccination if infant less than 9 months; if essential, consider temporary cessation of breastfeeding

5. Moderate Immunosuppression:

   • HIV with CD4 200-500 cells/μL
   • Low-dose immunosuppression
   • Approach: Specialist advice; may vaccinate if travel essential

6. Asymptomatic HIV (CD4 > 500 cells/μL):

   • Can be vaccinated but monitor antibody response

Vaccine-Associated Adverse Events

Common (Minor)

• Frequency: 10-30%
• Symptoms: Mild fever, headache, myalgia, injection site soreness
• Onset: 2-5 days post-vaccination
• Duration: 2-3 days
• Management: Symptomatic (paracetamol)

Rare but Serious

1. Yellow Fever Vaccine-Associated Neurotropic Disease (YEL-AND)

• Incidence: 0.4-0.8 per 100,000 doses (higher in infants and first-time vaccines > 60 years)
• Pathogenesis: Vaccine virus neurotropism causing CNS inflammation
• Clinical Presentations:
  • "Meningoencephalitis (most common): Fever, headache, confusion, seizures"
  • "Acute Disseminated Encephalomyelitis (ADEM): Multifocal demyelination"
  • Guillain-Barré Syndrome (GBS)
  • Myelitis
• Onset: 3-28 days post-vaccination
• Diagnosis: CSF pleocytosis, elevated protein; YFV-specific IgM in CSF; vaccine virus detected by RT-PCR in CSF
• Prognosis: Most patients recover with supportive care; neurological sequelae in ~10-20%; mortality less than 5%
• Management: Supportive; consider corticosteroids or IVIG for ADEM/GBS presentations [38,39]

2. Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD)

• Incidence: 0.3-0.4 per 100,000 doses (higher in elderly, thymus disorders)
• Pathogenesis: Uncontrolled vaccine virus replication mimicking wild-type YF disease (multi-organ failure)
• Risk Factors: Age > 60, thymus disorders (thymoma, thymectomy), underlying immunodeficiency
• Clinical Features: Identical to wild-type YF—fever, jaundice, hepatorenal failure, bleeding
• Onset: 2-10 days post-vaccination
• Diagnosis: Vaccine virus detected by RT-PCR in blood; rising transaminases, coagulopathy
• Prognosis: Case fatality rate: 60-80%—higher than wild-type disease
• Management: Intensive supportive care as per wild-type YF; consider sofosbuvir (experimental—case reports of success in post-exposure prophylaxis setting) [40,41]

3. Hypersensitivity Reactions

• Anaphylaxis: less than 0.1 per 100,000 doses
• Presentation: Urticaria, angioedema, bronchospasm, shock within minutes to hours
• Management: Adrenaline 0.5 mg IM, IV fluids, antihistamines, corticosteroids

Alternative Strategies if Vaccination Contraindicated

1. Medical Waiver Letter:

   • Issued by specialist/travel medicine physician documenting contraindication
   • Some countries accept waivers in lieu of ICVP
   • Not a Guarantee: Entry may still be refused

2. Vector Avoidance:

   • Insect repellent (DEET ≥50%, picaridin)
   • Long sleeves, trousers
   • Air-conditioned/screened accommodation
   • Mosquito nets

3. Reschedule/Reroute Travel:

   • Avoid endemic areas if possible

---

9. Prognosis and Outcomes

Prognosis by Severity

Outcomes in Severe Disease

Case Fatality Rate: 50-80% in toxic phase patients without intensive care; 30-50% with modern ICU support

Predictors of Mortality:

• Peak AST/ALT > 3,000 U/L
• Bilirubin > 200 μmol/L
• Severe thrombocytopenia (less than 20 x 10^9/L)
• Oliguria/anuria despite fluid resuscitation
• Development of hepatic encephalopathy
• Refractory shock requiring high-dose vasopressors
• Severe metabolic acidosis (lactate > 4 mmol/L)
• Age > 60 years

Time to Death: Usually 7-10 days after symptom onset (range: 5-14 days)

Survivors

Recovery: Patients who survive the toxic phase experience complete clinical and biochemical resolution. Convalescence typically requires 2-4 weeks.

Sequelae: Yellow fever does not cause chronic sequelae:

• No chronic liver disease or cirrhosis (unlike viral hepatitis B/C)
• No persistent neurological deficits (unlike Japanese encephalitis)
• No chronic kidney disease
• Liver regenerates completely

Immunity: Lifelong immunity following natural infection. No chronic carrier state or viral persistence.

Return to Work: Typically 4-8 weeks post-discharge depending on pre-morbid health and severity

Long-term Follow-up

• Liver Function: Normalises within 4-12 weeks; repeat LFTs at 3 months
• Renal Function: Most patients recover renal function; small proportion may have residual impairment requiring monitoring
• Vaccination: Unnecessary (lifelong immunity from natural infection)

---

10. Complications

---

11. Public Health and Epidemiological Considerations

International Health Regulations

Yellow fever is one of three diseases requiring notification under WHO International Health Regulations (alongside cholera and plague). All confirmed or suspected cases must be reported to national public health authorities, who notify WHO.

Risk of Urbanisation

The re-emergence of urban yellow fever represents a major global health security threat:

• Aedes aegypti highly adapted to urban environments
• Widespread distribution including naïve populations (Asia, Southern USA, Mediterranean)
• Low vaccination coverage in many at-risk areas
• Climate change expanding mosquito range

Urban outbreaks have occurred in Angola (2016), Brazil (2017-2018), Nigeria (ongoing), demonstrating continued risk. [42]

The "Asia Enigma"

Mystery: Despite presence of competent Aedes aegypti vectors and high dengue endemicity, yellow fever has never become established in Asia.

Hypotheses:

1. Cross-Protective Immunity: High seroprevalence of dengue antibodies may provide partial protection
2. Vector Incompetence: Asian Aedes aegypti populations may have lower vectorial capacity for YFV
3. Viral Genetics: Lack of introduction of specific YFV genotypes adapted to Asian vectors
4. Ecological Factors: Absence of sylvatic reservoir (no suitable primate populations)

Implications: Billions of unvaccinated people in Asia remain susceptible; introduction could cause catastrophic pandemic. [43]

Vaccine Supply and Global Stockpiles

• Global Demand: Exceeds supply during outbreaks
• Emergency Stockpile: WHO maintains 6 million dose emergency stockpile for outbreak response
• Fractional Dosing: During shortages, 1/5th dose provides immunity (used in outbreak settings—Kinshasa 2016) [44]

---

12. Key Guidelines and Evidence Base

Major Guidelines

Landmark Studies and Historical Milestones

1. Walter Reed Commission (1900)

• Discovery: Proved mosquito transmission of YFV by Aedes aegypti
• Impact: Enabled control through vector elimination (Panama Canal construction)
• Method: Human volunteer experiments (ethical controversy)

2. Max Theiler - 17D Vaccine Development (1937)

• Achievement: Live-attenuated vaccine strain through serial passage in mouse embryo and chick embryo tissue
• Nobel Prize: 1951 in Physiology or Medicine
• Legacy: Same vaccine strain still in use 85+ years later [45]

3. WHO Yellow Fever Initiative (2006-present)

• Goal: Prevent urban outbreaks through preventive mass vaccination campaigns in Africa
• Achievement: > 180 million people vaccinated 2007-2021
• Impact: Reduced burden in targeted countries but ongoing challenges with coverage and supply

4. Monath & Vasconcelos (2015) - Pathogenesis Review

• Comprehensive review of YFV pathophysiology and NS1-mediated endothelial dysfunction
• PMID: 25453327 [1]

5. Seligman (2014) - YEL-AVD Risk Groups

• Defined risk groups for vaccine-associated viscerotropic disease
• Established thymus disorders as major risk factor
• PMID: 25192973 [33]

---

13. Examination Focus

Common Exam Questions (MRCP, FRACP, PLAB, USMLE)

Written Exam (MCQ/SBA)

1. "A 35-year-old man returns from Nigeria with fever, jaundice, and bradycardia. AST 4,500 U/L, ALT 2,800 U/L. Most likely diagnosis?"

   • Answer: Yellow fever (AST > ALT with bradycardia and jaundice in returned traveller from endemic area)

2. "Which of the following is an absolute contraindication to yellow fever vaccination?"

   • Answer: History of thymectomy (any age, any indication)

3. "What is the mechanism of Faget's sign in yellow fever?"

   • Answer: Relative bradycardia despite high fever due to direct viral effects on cardiac conduction system

4. "A patient with yellow fever develops black vomit. This indicates?"

   • Answer: Gastrointestinal haemorrhage from coagulopathy—poor prognostic sign (toxic phase)

5. "Which investigation is most specific for acute yellow fever diagnosis in first 4 days of illness?"

   • Answer: RT-PCR for YFV RNA in serum (viral detection during viremia)

Clinical Exam (PACES, OSCE)

Scenario: "This returned traveller has fever and jaundice. Please take a focused history."

Key Points to Elicit:

• Travel history (destination, dates, activities)
• Vaccination status (yellow fever vaccine, timing)
• Mosquito exposure (bites, protective measures)
• Symptom timeline (biphasic fever pattern?)
• Associated symptoms (bleeding, dark urine, abdominal pain)

Red Flags to Identify:

• Jaundice + oliguria
• Haemorrhagic manifestations
• Bradycardia with fever

Viva Voce Points

Viva Point: Opening Statement: "Yellow fever is an acute viral haemorrhagic fever caused by the yellow fever virus, an arthropod-borne flavivirus transmitted by Aedes mosquitoes in tropical Africa and South America. It is characterised by a biphasic illness with an initial viremic phase followed by a toxic phase of hepatorenal failure, haemorrhage, and shock in approximately 15% of cases, carrying 50-80% mortality."

Key Facts to Mention:

• Epidemiology: 200,000 cases and 30,000 deaths annually; 90% in Africa [1]
• Pathognomonic Features: Faget's sign (relative bradycardia), black vomit (vomito negro), AST > ALT ratio
• Diagnosis: RT-PCR in acute phase; IgM serology from day 5 onwards
• No Specific Treatment: Supportive care only; investigational sofosbuvir
• Prevention: 17D live-attenuated vaccine—single dose, lifelong protection, > 95% efficacy [10]
• Vaccine Contraindications: Thymus disorders (thymoma/thymectomy), severe immunodeficiency, age less than 6 months, egg allergy
• Vaccine Risks: YEL-AVD (0.3-0.4 per 100,000; 60-80% fatal) and YEL-AND (0.4-0.8 per 100,000; mostly recoverable) [33,38]

Structured Approach to Management: "I would manage this patient in an intensive care setting with mosquito-proof isolation. Management is entirely supportive focusing on haemodynamic stabilisation with cautious fluid resuscitation and vasopressors if needed, correction of coagulopathy with FFP and platelets guided by bleeding and laboratory parameters, renal replacement therapy for severe AKI or refractory acidosis, and prevention of secondary bacterial infection. I would notify public health authorities immediately as this is a notifiable disease. For prevention, I would ensure at-risk travellers receive yellow fever vaccination at least 10 days prior to travel unless contraindicated."

Common Mistakes to Avoid

❌ Mistakes that Fail Candidates:

1. Failing to Recognise Geographic Restriction:

   • Saying yellow fever is endemic in Asia (it is NOT—never established there)
   • Not asking about Africa/South America travel history

2. Misinterpreting Liver Biochemistry:

   • Expecting ALT > AST (typical of viral hepatitis)
   • YF characteristically shows AST > ALT (ratio > 1.5)

3. Recommending Aspirin or NSAIDs:

   • Contraindicated due to bleeding risk (thrombocytopenia + coagulopathy)
   • Use paracetamol for fever

4. Claiming There Is Specific Antiviral Treatment:

   • No proven antiviral therapy (management is supportive)
   • Sofosbuvir is investigational only

5. Forgetting Isolation and Notification:

   • Patient must be isolated under mosquito net during viremic phase (prevent local transmission)
   • Immediate notification to public health authorities (IHR requirement)

6. Vaccinating Contraindicated Patients:

   • Thymoma/thymectomy is ABSOLUTE contraindication (5-10x increased YEL-AVD risk)
   • Age > 60 requires careful risk-benefit assessment (not blanket avoidance, but caution)

7. Stating Booster Vaccines Are Needed:

   • WHO removed 10-year booster requirement in 2016
   • Single dose provides lifelong immunity

Model Answers

Q: "Describe your approach to investigating a febrile returned traveller with jaundice."

A: "I would take a detailed travel history including specific destinations, dates of travel, activities (forest exposure, water contact), and vaccination status including yellow fever, hepatitis A, and typhoid vaccines. I would ask about the timeline and pattern of symptoms—specifically enquiring about a biphasic fever pattern which would suggest yellow fever or leptospirosis.

My initial investigations would include full blood count looking for thrombocytopenia and leucopenia, liver function tests with particular attention to the AST/ALT ratio, coagulation studies, renal function, and a blood film for malaria parasites given that malaria is the most common cause of fever in returned travellers from endemic areas.

For specific diagnoses, I would send thick and thin blood films and malaria rapid antigen test, and based on the destination, I would consider dengue serology and NS1 antigen, yellow fever RT-PCR and serology if returning from sub-Saharan Africa or South America with unvaccinated status, leptospirosis serology if there was freshwater exposure, and hepatitis A IgM.

If yellow fever is suspected based on epidemiology and AST-predominant hepatitis with thrombocytopenia, I would isolate the patient under mosquito-proof conditions, notify public health authorities immediately, and initiate intensive supportive care while awaiting RT-PCR confirmation."

---

Q: "A 65-year-old man is planning travel to Brazil. He asks about yellow fever vaccination. How would you advise him?"

A: "I would conduct a thorough pre-travel risk assessment. First, I would determine the specific areas of Brazil he is visiting—yellow fever is endemic in the Amazon basin and certain other regions but not in coastal cities like Rio de Janeiro or São Paulo. I would ask about the duration and nature of his trip.

I would then assess for contraindications to yellow fever vaccination. Critical questions include: any history of thymus problems including thymoma or thymectomy, which are absolute contraindications; any immunosuppression including HIV, cancer, or immunosuppressive medications; and any severe allergies to egg protein or previous vaccine reactions.

Given his age of 65 years, I would explain that elderly individuals have a 3-4 fold increased risk of serious vaccine-associated adverse events, particularly YEL-AVD which carries 60-80% mortality, and YEL-AND. However, if travel to a high-risk endemic area is essential and cannot be avoided or rescheduled, the benefits of vaccination typically outweigh the risks.

If he has no absolute contraindications, I would recommend vaccination if travelling to endemic regions, emphasising that it should be administered at least 10 days before travel, provides lifelong protection after a single dose, and generates an International Certificate of Vaccination which may be required for entry to certain countries.

If vaccination is contraindicated or he declines due to age-related risks, I would discuss alternative strategies including strict mosquito bite avoidance with DEET-containing repellent, protective clothing, and staying in air-conditioned or screened accommodation, or reconsidering travel to non-endemic areas of Brazil."

---

14. References

1. Monath TP, Vasconcelos PFC. Yellow fever. J Clin Virol. 2015;64:160-173. doi:10.1016/j.jcv.2014.08.030

2. Garske T, Van Kerkhove MD, Yactayo S, et al. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11(5):e1001638. doi:10.1371/journal.pmed.1001638

3. Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003;60:343-395. doi:10.1016/s0065-3527(03)60009-6

4. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44(6):850-856. doi:10.1086/511869

5. Barrett ADT, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol. 2007;52:209-229. doi:10.1146/annurev.ento.52.110405.091454

6. Wilder-Smith A, Monath TP. Responding to the threat of urban yellow fever outbreaks. Lancet Infect Dis. 2017;17(3):248-250. doi:10.1016/S1473-3099(16)30588-6

7. World Health Organization. Yellow fever – fact sheet. WHO; 2023. https://www.who.int/news-room/fact-sheets/detail/yellow-fever

8. Bryant JE, Holmes EC, Barrett AD. Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog. 2007;3(5):e75. doi:10.1371/journal.ppat.0030075

9. Hamlet A, Jean K, Perea W, et al. The seasonal influence of climate and environment on yellow fever transmission across Africa. PLoS Negl Trop Dis. 2018;12(3):e0006284. doi:10.1371/journal.pntd.0006284

10. Staples JE, Bocchini JA Jr, Rubin L, Fischer M. Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):647-650.

11. Possas C, Lourenço-de-Oliveira R, Tauil PL, et al. Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation. Mem Inst Oswaldo Cruz. 2018;113(10):e180278. doi:10.1590/0074-02760180278

12. Mir D, Delatorre E, Bonaldo M, et al. Phylodynamics of yellow fever virus in the Americas: new insights into the origin of the 2017 Brazilian outbreak. Sci Rep. 2017;7(1):7385. doi:10.1038/s41598-017-07873-7

13. Mutebi JP, Barrett AD. The epidemiology of yellow fever in Africa. Microbes Infect. 2002;4(14):1459-1468. doi:10.1016/s1286-4579(02)00028-x

14. Engelmann F, Josset L, Girke T, et al. Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model. PLoS Negl Trop Dis. 2014;8(11):e3295. doi:10.1371/journal.pntd.0003295

15. Quaresma JA, Barros VL, Pagliari C, et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology. 2006;345(1):22-30. doi:10.1016/j.virol.2005.09.058

16. Puerta-Guardo H, Glasner DR, Espinosa DA, et al. Flavivirus NS1 triggers tissue-specific vascular endothelial dysfunction reflecting disease tropism. Cell Rep. 2019;26(6):1598-1613.e8. doi:10.1016/j.celrep.2019.01.036

17. ter Meulen J, Sakho M, Koulemou K, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis. 2004;190(10):1821-1827. doi:10.1086/425016

18. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341(8):586-592. doi:10.1056/NEJM199908193410807

19. Woodson SE, Holbrook MR. Infection and persistence of Rift Valley fever virus in human monocyte-derived macrophages and dendritic cells. Virology. 2011;419(2):88-95. doi:10.1016/j.virol.2011.08.006

20. Douam F, Ploss A. Yellow fever virus: knowledge gaps impeding the fight against an old foe. Trends Microbiol. 2018;26(11):913-928. doi:10.1016/j.tim.2018.05.012

21. Qiu X, Bailey AL. Two mutations in NS2B are responsible for attenuation of the yellow fever virus (YFV) vaccine strain 17D. PLoS Pathog. 2025;21(7):e1013373. doi:10.1371/journal.ppat.1013373

22. Sutherland DM, Aicher SM, Anderson EM, et al. Genetic basis of differential antibody responses to yellow fever vaccination in humans. bioRxiv. 2021. doi:10.1101/2021.09.03.458750

23. Van der Stuyft P, Gianella A, Pirard M, et al. Urbanisation of yellow fever in Santa Cruz, Bolivia. Lancet. 1999;353(9164):1558-1562. doi:10.1016/S0140-6736(99)03291-2

24. Tuboi SH, Costa ZG, da Costa Vasconcelos PF, Hatch D. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002. Trans R Soc Trop Med Hyg. 2007;101(2):169-175. doi:10.1016/j.trstmh.2006.04.001

25. Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. Trans R Soc Trop Med Hyg. 2014;108(8):482-487. doi:10.1093/trstmh/tru092

26. Cordeiro MT, Pena LJ, Brito CA, et al. Positive IgM for Zika virus in the cerebrospinal fluid of 30 neonates with microcephaly in Brazil. Lancet. 2016;387(10030):1811-1812. doi:10.1016/S0140-6736(16)30253-7

27. Quaresma JA, Pagliari C, Medeiros DB, et al. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev Med Virol. 2013;23(5):305-318. doi:10.1002/rmv.1752

28. Julander JG, Siddharthan V, Evans J, et al. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Res. 2017;137:14-22. doi:10.1016/j.antiviral.2016.11.003

29. Barrett J, Muntengesa E, Warrell C, et al. Sofosbuvir as post-exposure prophylaxis for yellow fever-associated viscerotropic disease (YEL-AVD). J Antimicrob Chemother. 2025;80(3):825-827. doi:10.1093/jac/dkae484

30. de Freitas CS, Higa LM, Sacramento CQ, et al. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. PLoS Negl Trop Dis. 2019;13(1):e0007072. doi:10.1371/journal.pntd.0007072

31. Piras-Douce F, Raynal F, Raquin A, et al. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models. Vaccine. 2021;39(13):1846-1856. doi:10.1016/j.vaccine.2021.02.033

32. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89(3):434-444. doi:10.4269/ajtmh.13-0264

33. Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014;32(44):5769-5775. doi:10.1016/j.vaccine.2014.08.051

34. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077-6082. doi:10.1016/j.vaccine.2008.09.009

35. Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-7):1-27.

36. Rafferty E, Duclos P, Yactayo S, Schuster M. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine. 2013;31(49):5798-5805. doi:10.1016/j.vaccine.2013.09.030

37. Suzano CE, Amaral E, Sato HK, Papaiordanou PM. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine. 2006;24(9):1421-1426. doi:10.1016/j.vaccine.2005.09.033

38. Lecomte E, Laureys G, Verbeke F, et al. A clinician's perspective on yellow fever vaccine-associated neurotropic disease. J Travel Med. 2020;27(7):taaa172. doi:10.1093/jtm/taaa172

39. Cohen M, Nguyen M, Nix CD, et al. Case report: Yellow fever vaccine-associated neurotropic disease and associated MRI, EEG, and CSF findings. Front Neurol. 2021;12:779014. doi:10.3389/fneur.2021.779014

40. Muñoz J, Vilella A, Domingo C, et al. Yellow fever-associated viscerotropic disease in Barcelona, Spain. J Travel Med. 2008;15(3):202-205. doi:10.1111/j.1708-8305.2008.00209.x

41. Thomas RE, Lorenzetti DL, Springall E, Jackson D, Williamson T. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg. 2012;86(2):359-372. doi:10.4269/ajtmh.2012.11-0525

42. Shearer FM, Moyes CL, Pigott DM, et al. Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 2017;17(11):1209-1217. doi:10.1016/S1473-3099(17)30419-X

43. Jentes ES, Poumerol G, Gershman MD, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011;11(8):622-632. doi:10.1016/S1473-3099(11)70147-5

44. Casey RM, Harris JB, Ahuka-Mundeke S, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak - final report. N Engl J Med. 2019;381(5):444-454. doi:10.1056/NEJMoa1710430

45. Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med. 1937;65(6):787-800. doi:10.1084/jem.65.6.787

46. de Sousa FTG, Warnes CM, Manuli ER, et al. Yellow fever disease severity and endothelial dysfunction are associated with elevated serum levels of viral NS1 protein and syndecan-1. EBioMedicine. 2024;109:105409. doi:10.1016/j.ebiom.2024.105409

47. Puerta-Guardo H, Glasner DR, Espinosa DA, et al. Flavivirus NS1 triggers tissue-specific vascular endothelial dysfunction reflecting disease tropism. Cell Rep. 2019;26(6):1598-1613.e8. doi:10.1016/j.celrep.2019.01.036

48. Bailey AL, Kang LI, D'Elia Zanella LGFAB, et al. Consumptive coagulopathy of severe yellow fever occurs independently of hepatocellular tropism and massive hepatic injury. Proc Natl Acad Sci U S A. 2020;117(51):32648-32656. doi:10.1073/pnas.2014096117

49. Coulter FJ, Messer WB. Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades. Vaccine. 2025;43(Pt 1):126423. doi:10.1016/j.vaccine.2024.126423

50. Vianna CM, Noronha TG, Camacho LAB, et al. Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study - A complementary study. Vaccine. 2024;42(24):126083. doi:10.1016/j.vaccine.2024.06.050

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and refer to the most current guidelines. Yellow fever is a notifiable disease requiring immediate public health notification.